Evidence map›Paper›PMID 41390988›Full record

Trial reportClinical and translational science2025

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.

Ashley L Lennox, Fei Huang, Mario González-Sales, Ying Wan, Libo Sun, Tymara Berry, Faye Feller, Peter N Morcos

Registry-linked trialAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraph

Trial report in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02598661 (A Study to Evaluate Imetelstat), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02598661 phase2 / phase3active not recruitingnot on this map

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

TypeinterventionalSponsorGeron CorporationRan2016 to 2026Enrolled289ConditionsMyelodysplastic SyndromesArmsImetelstat Sodium, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ashley L LennoxGeron Corporation, Foster City, California, USA.
Fei HuangGeron Corporation, Foster City, California, USA.
Mario González-SalesModeling Great Solutions Pharmaceutical Research & Studies, FZE, Dubai, UAE.
Ying WanGeron Corporation, Foster City, California, USA.
Libo SunGeron Corporation, Foster City, California, USA.
Tymara BerryGeron Corporation, Foster City, California, USA.
Faye FellerGeron Corporation, Foster City, California, USA.
Peter N MorcosMorcos Pharmaceutical Consulting, LLC, Marlboro, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imetelstat is a first-in-class, 13-mer oligonucleotide telomerase inhibitor approved in the United States and European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with red blood cell (RBC) transfusion-dependent anemia. This post hoc analysis evaluated imetelstat immunogenicity and its association with the pharmacokinetics (PK), efficacy, and safety of imetelstat in patients with LR-MDS from the phase II/III IMerge study (NCT02598661). A validated, semi-quantitative 3-tiered method evaluated anti-drug antibodies (ADAs). Graphical and descriptive analyses evaluated ADA incidence and association with clinical outcomes. Of 166 evaluable patients who received 7.1 mg/kg imetelstat via a 2-h intravenous infusion every 4 weeks, 16.9% developed imetelstat ADAs (median [range] time to onset, 38 weeks [12-109]; ~8 treatment cycles). In ADA-positive patients, peak titer was low (median [range], 30 [10-160]). Evaluations showed no association of ADA positivity with imetelstat PK, nor any negative association with efficacy responses, including ≥ 8-week RBC-transfusion independence (TI), ≥ 24-week RBC-TI, hematologic improvement-erythroid, or duration of RBC-TI response. There was no apparent relationship between the onset of ADAs and loss of RBC-TI. The rates of any-grade or grade ≥ 3 treatment-emergent adverse events (TEAEs) were similar for both ADA groups, with no reported serious TEAEs or TEAEs causing death in ADA-positive patients. Infusion-related TEAEs were more frequent in ADA-positive patients, although the sample size was small. Overall, imetelstat ADAs did not appear to impact imetelstat benefit/risk profile in the LR-MDS population of IMerge, although the analysis is limited by the low incidence of imetelstat ADAs, resulting in a small ADA-positive group.

Indexed as

Enzyme InhibitorsMyelodysplastic SyndromesOligonucleotidesTelomeraseAdultAgedAged, 80 and overAntibodiesErythrocyte TransfusionFemaleHumansInfusions, IntravenousMaleMiddle AgedTreatment OutcomeAntibodiesEnzyme InhibitorsimetelstatOligonucleotidesTelomeraseimetelstatimmunogenicitymyelodysplastic syndromesmyelofibrosispharmacokineticstelomerase inhibitor

Identifiers

PMID41390988
PMCPMC12702135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.